InflaRX
Würzburg, Germany · Founded 2007
- Headquarters
- Würzburg
- Employees
- 51–200
- Founded
- 2007
- Business Model
- B2B
- Website
- inflarx.de
About
InflaRx is a clinical-stage biopharmaceutical company founded in December 2007 in Jena, Germany, pioneering anti-inflammatory therapeutics that target the complement system, particularly C5a and its receptor C5aR. Its lead product, GOHIBIC (vilobelimab), received FDA Emergency Use Authorization for severe COVID-19 and EU marketing authorization for ARDS. InflaRx completed its Nasdaq IPO in November 2017 and maintains offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA.
Summary
InflaRX is a Biotech company based in Würzburg, Germany, founded in 2007.
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...